The anatomic pathology market was valued at USD 16.2 billion in 2016 and poised to grow at a CAGR of 6.1% between 2016 and 2021, to reach USD 21.9 billion in 2021.
Anatomic pathology is used for the diagnosis of various types of chronic diseases such as cancer and infectious diseases. Moreover, it is used in the pharmaceutical industries to conduct toxicology studies. The anatomic pathology market is witnessing high growth due to factors such as increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure.
Based on product & service, the anatomic pathology market is segmented into instruments, consumables, and services. The instruments segment has been subsegmented into tissue processing systems, slides staining systems, microtomes, and other instruments. Similarly, the consumables segment has been subsegmented into reagents & antibodies, probes, kits, and other consumables.
Likewise, the services segment has been subsegmented into cytopathology, histopathology, and other services. In 2016, the services segment accounted for the largest share of the market. This growth can be attributed to the increasing prevalence of chronic diseases and the subsequent growth in the number of anatomic pathology tests.
- Agilent Technologies, Inc.
- Bio SB
- Biogenex Laboratories
- Danaher Corporation
- F. Hoffmann-La Roche AG.
- Laboratory Corporation of America Holdings
- Neogenomics Laboratories, Inc.
- Quest Diagnostics Incorporated
- Sakura Finetechnical Co.
Thermo Fisher Scientific
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Anatomic Pathology Market, By Product & Service
7 Anatomic Pathology Market, By Application
8 Anatomic Pathology Market, By Region
9 Competitive Landscape
10 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/xmrmps/anatomic